Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Genmab ( (GMAB) ) just unveiled an announcement.
On September 9, 2025, Genmab A/S announced a capital increase of 47,532 shares following the exercise of employee warrants, generating approximately DKK 51.5 million. This increase, which represents about 0.07% of the company’s share capital, includes the exercise of 23,266 warrants by CEO Jan van de Winkel. The new shares, ordinary and freely transferable, will be listed on Nasdaq Copenhagen, enhancing Genmab’s market position and potentially benefiting stakeholders by increasing the company’s equity base.
The most recent analyst rating on (GMAB) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s overall stock score is driven by strong earnings call results and positive technical indicators, highlighting robust growth prospects and market momentum. The company’s solid financial performance, despite recent revenue and cash flow challenges, supports its stability. Valuation metrics suggest the stock is undervalued, offering potential upside. The absence of significant corporate events does not impact the score.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab is an international biotechnology company focused on developing innovative antibody therapeutics to improve the lives of patients. Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific. The company leverages next-generation antibody technology platforms and has a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and other advanced therapeutic solutions.
Average Trading Volume: 1,368,585
Technical Sentiment Signal: Buy
Current Market Cap: $16.99B
Find detailed analytics on GMAB stock on TipRanks’ Stock Analysis page.